Abstract:The oral glucose tolerance test is still the definitive test for diagnosing diabetes mellitus, although the diagnosis can be made without the test when the patient has typical features of the disease and a raised plasma glucose concentration. Many glucose tolerance tests are carried out in hospitals, with the average hospital laboratory performing about five a week (with considerable variation between individual hospitals).' Nevertheless, despite recent attempts to try to standardise the procedure for both performing and interpreting the test,2-5 a recent survey has shown that agreed protocols, such as that of the World Health Organisation expert committee,3'5 are not always followed. As an example, the World Health Organisation specifies a fasting period of 10 to 16 hours.5 Most ofthe respondents to a questionnaire sent out by a working party of the Association of Clinical Biochemists said that they fasted patients for between nine and 14 hours, but a tenth simply asked patients to fast "overnight" and a few asked them to fast for as little as five hours. Previous carbohydrate intake may also influence the glycaemic response and an unrestricted diet containing at least 150 g of carbohydrate a day is advised for the three days before the test.5 Nevertheless, most laboratories assumed that this was the case without actually specifying it. Over four fifths of hospitals were using the currently recommended 75 g load of glucose,5 but the remainder were using 50 g. Another difference in approach is the type of glucose used. The World Health Organisation recommends using 75 g of glucose but does not say whether this is anhydrous glucose or the monohydrate; hence some centres are using one form and some the other, with a resultant difference of about 10% in the actual load ofglucose given. Though this discrepancy in a total dose ofabout 75 g may not evoke much difference in the blood sugar response, it is an undesirable and avoidable potential source ofvariation. As the monohydrate is the most readily available form, it would seem sensible to standardise on this. Again, about a fifth of laboratories used proprietary liquid preparations of partially hydrolysed starch (such as Lucozade), but sometimes the volume used differed from that recommended. The World Health Organisation criteria for interpreting the results ofthe glucose tolerance test vary depending on the type of specimen used-for example venous whole blood, venous plasma, or capillary whole blood. The 1980 World Health Organisation report gave no figures for capillary plasma,3 which was used by a tenth of the participants in the survey and will in some instances yield higher results than venous plasma. The 1985 World Health Organisation report does, however, include figures for capillary plasma,5 but probably many laboratory staff and clinicians are still unaware of the more recent document. Clearly when interpreting the results ofa glucose tolerance test the doctor must know about such influencing factors and what protocol was used. Failure to pay attention to this type of detail might lead to a patient being incorrectly classified as a diabetic, with lifelong consequences-medical, social, legal, and financial. A degree of glucose tolerance intermediate between normality and diabetes, termed "impaired glucose tolerance," does not necessarily foreshadow diabetes, and indeed may revert to normal; hence it should not be regarded in the same way as a diagnosis of definite diabetes. The results of glucose tolerance tests are often reported without any comment to clinicians. Even if they are familiar with theWorld Health Organisation criteria for classification, they may not know the details of their own laboratory's procedure and hence may misinterpret the results using the wrong set of figures. Such a pitfall may be avoided by closer cooperation between the laboratory and the clinician. The laboratory should be able to offer an interpretation or at least to advise on the best criteria to use; if this information is not volunteered the clinician should ask for it. K WIENER

Quantitative analysis of new generation antidepressants using gas chromatography-mass spectrometry: applications in clinical and forensic toxicology

Two Approaches towards the Formalisation of VDM

Simultaneous Quantification Of 38 Psychotropic Drugs And Relevant Metabolites In Blood Using Lc-Ms-Ms

An in-depth analysis of four classes of antidepressants quantification from human serum using LC-MS/MS

Comments on Birch and Abelson's “Is Reasonable Access What We Want?”

Determination of antidepressants in whole blood using hollow-fiber liquid-phase microextraction and gas chromatography–mass spectrometry

Validated simultaneous high-performance thin-layer chromatography‒mass spectrometry method for analysis of citalopram prochlorperazine, midazolam, and chlorodiazepoxide in urine for forensic analysis

Diagnosis of diabetes mellitus: pitfalls in the glucose tolerance test.

Unravelling psychoactive substances and their metabolites and transformation products: High-Resolution Mass Spectrometry approaches for comprehensive target and suspect screening in wastewater

Quantitative determination of fifteen basic pharmaceuticals in ante- and post-mortem whole blood by high pH mobile phase reversed phase ultra high performance liquid chromatography-tandem mass spectrometry

Simultaneous Quantification of Antidepressants and Metabolites in Urine and Plasma Samples by GC–MS for Therapeutic Drug Monitoring

Trace analysis of 47 psychotropic medications in environmental samples by ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS)

Current state-of-the-art approaches for mass spectrometry in clinical toxicology: an overview

Liquid Chromatography High Resolution Mass Spectrometry in Forensic Toxicology: What Are the Specifics of Method Development, Validation and Quality Assurance for Comprehensive Screening Approaches?

Food as a Hormone

Simple and sensitive screening and quantitative determination of 88 psychoactive drugs and their metabolites in blood through LC-MS/MS: application on postmortem samples

Defaecation: a study using radiopaque markers.

Guilty by dissociation—development of gas chromatography–mass spectrometry (GC-MS) and other rapid screening methods for the analysis of 13 diphenidine-derived new psychoactive substances (NPSs)

Multi-Class Analysis of 57 Drugs Quantitatively in Blood and Qualitatively in Urine by LC-MS/MS to Complement Comprehensive DFC, DUID and Postmortem Testing

Comparison of Various Chromatographic Systems for Identification of Vortioxetine in Bulk Drug Substance, Human Serum, Saliva, and Urine Samples by HPLC-DAD and LC-QTOF-MS

Fluorescence in situ hybridization in cancer diagnosis.